Education
About Us
Working with TipRanks
Follow Us
Henry Schein (HSIC)
NASDAQ:HSIC
Earnings Data
Report Date
May 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.22Last Year’s EPS
1.15Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive operational and commercial picture: strong top‑line momentum across core businesses (especially equipment, specialty products, and technology), improving SaaS traction and AI partnerships, solid cash flow, share buybacks, and explicit value‑creation targets. Offsetting items include margin pressure from mix, sizable restructuring costs in 2025, softness in respiratory/medical demand, and uncertainty around remeasurement gains and tariff exposure. Management expects 2026 improvement to be back‑half weighted and provided mid‑single to low‑single digit growth guidance, reflecting cautious optimism.Company Guidance
Strong Quarterly and Year‑over‑Year Sales Growth
Q4 global sales of $3.4 billion, up 7.7% year‑over‑year (5.8% constant currency; +1.9% FX benefit). Acquisitions contributed 0.9% of quarterly sales growth. Company reported the highest sales growth in 15 quarters and momentum continued into January 2026.
Segment-Outperformance — Equipment and International
U.S. dental equipment sales grew 10.6% (double‑digit traditional equipment growth); international dental equipment sales grew 13.9% (7.5% constant currency). Digital equipment unit growth positive (2D/3D imaging, mills, 3D printers, intraoral scanners).
Global Specialty Products Acceleration
Global Specialty Products sales grew 14.6% (11.1% constant currency). Implants and biomaterials delivered strong results with value implants up double digits and premium implants up mid‑single digits; notable double‑digit contributors included BioHorizons Camlog (Germany), SIN (Brazil) and Biotech (France). SIN value implant introduced in the U.S. in Q4 2025.
Technology & SaaS Momentum
Global Technology Group sales up 8.4% (7.6% constant currency). Cloud‑based customers increased >20% year‑over‑year with more than 11,000 Dentrix Ascend subscribers. Recurring SaaS revenue and transactional services growing; launched AI initiatives with AWS (generative/agentic AI), Voice Notes, ImageVerify, improved Eligibility Pro and automated forms workflows.
Profitability and EPS Improvements (Non‑GAAP and GAAP)
Q4 GAAP net income $101 million ($0.85 diluted EPS) vs $94 million ($0.74) prior year. Q4 non‑GAAP net income $160 million ($1.34 diluted EPS) vs $149 million ($1.19) prior year. Non‑GAAP operating margin for Q4 was 7.42%, relatively flat year‑over‑year despite lower gross margins.
Cash Flow and Capital Allocation
Operating cash flow in Q4 was $381 million vs $204 million in Q4 2024 (strong working capital improvement). During 2025 the company repurchased ~2.8 million shares for $200 million at an average price of $71.10; ~$780 million authorized and available for future repurchases at year‑end.
Value‑Creation Targets and Guidance
Company expects >$200 million of operating income improvement over the next few years from value‑creation initiatives, with annual run‑rate operating income improvement of over $125 million by 2026. 2026 guidance: sales growth 3%–5%; non‑GAAP diluted EPS $5.23–$5.37 (5%–8% growth vs 2025 non‑GAAP EPS of $4.97); 2026 adjusted EBITDA expected to grow mid‑single digits vs 2025 adjusted EBITDA of ~$1.1 billion.
Strategic and Commercial Wins
Rolled out global e‑commerce platform (henryschein.com) with U.S. dental and Canadian rollouts expected early 2026; exclusive U.S. and U.K. distribution for Novartis' Curaden product; signed exclusive U.S. distribution for CytoChip's CytoCBC point‑of‑care CBC system; strengthened supplier partnerships and data‑driven marketing adoption (Henry Schein One eClaims data shows stable/modestly positive procedure trends).
HSIC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HSIC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $80.57 | $83.35 | +3.45% |
Nov 04, 2025 | $64.64 | $71.61 | +10.78% |
May 05, 2025 | $65.30 | $66.58 | +1.96% |
Feb 25, 2025 | $77.64 | $75.82 | -2.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Henry Schein (HSIC) report earnings?
Henry Schein (HSIC) is schdueled to report earning on May 12, 2026, Before Open (Confirmed).
What is Henry Schein (HSIC) earnings time?
Henry Schein (HSIC) earnings time is at May 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HSIC EPS forecast?
HSIC EPS forecast for the fiscal quarter 2026 (Q1) is 1.22.